We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Emma
Hall
emma.hall@icr.ac.uk
Miss
Katie
Biscombe
PBTRecruitment-icrctsu@icr.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
It is unknown whether the results of clinical trials evaluating state-of-the-art advanced radiotherapy technologies are generalisable to the target patient population as there may be additional barriers to recruitment. In addition to the usual considerations around study participation, advanced technologies such as proton beam therapy and MR Linac therapy are only available at a small number of specialist sites meaning that travel and a stay away from home may be necessary for treatment at a distant hospital and hence participation in the study. Such factors could influence a patient’s decision to participate in such a trial and could mean that certain demographics are inadvertently excluded from the research. In order to inform future studies using advanced radiotherapy techniques such as proton beam therapy, we need to understand more about the patients that decline participation.
Patients who were eligible but decline participation in a UK proton beam therapy study will be asked to complete an optional one off optional questionnaire. Patients who accept participation in a UK proton beam therapy study will be asked to (optionally) consent to sharing of basic demographic data to allow comparison of decliners and acceptors. Up to 100 patients will be recruited.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
none
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Miss
Katie
Biscombe
PBTRecruitment-icrctsu@icr.ac.uk
Dr
Emma
Hall
emma.hall@icr.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Institute of Cancer Research: Royal Cancer Hospital and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 51346
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
